Interference No. 103,625
Seq.1 H Thr Pro Tyr Ala Pro Glu Pro Gly Ser Thr Cys Arg Leu Arg Glu
Seq. 2 Phe Thr Pro Tyr Ala Pro Glu Pro Gly Ser Thr Cys Arg Leu Arg Glu
Seq. 3 Ala Phe Thr Pro Tyr Ala Pro Glu Pro Gly Ser Thr Cys Arg Leu Arg Glu
Seq. 4 Val Ala Phe Thr Pro Tyr Ala Pro Glu Pro Gly Ser Thr Cys Arg Leu Arg Glu
Seq. 5 Gln Val Ala Phe Thr Pro Tyr Ala Pro Glu Pro Gly Ser Thr Cys Arg Leu Arg Glu
Seq. 6 Ala Gln Val Ala Phe Thr Pro Tyr Ala Pro Glu Pro Gly Ser Thr Cys Arg Leu Arg Glu
Seq. 7 Pro Ala Gln Val Ala Phe Thr Pro Tyr Ala Pro Glu Pro Gly Ser Thr Cys Arg Leu Arg Glu
Seq. 8 Leu Pro Ala Gln Val Ala Phe Thr Pro Tyr Ala Pro Glu Pro Gly Ser Thr Cys Arg Leu Arg Glu
Claim 2 requires the protein of claim 1 to be in deglycoslated form.
Claim 3 is directed to the process for preparation of the protein of claim 1
comprising concentrating the urine of patients with a fever and subsequent purification of
the retentate obtained in this way by ion exchange and affinity chromatography.
Benefit to antedate a reference
A party may antedate prior art by relying on the benefit of an earlier filed
foreign application to establish an effective date earlier than that of the reference. 35
U.S.C. § 119. To be entitled to the benefit of an earlier filed application, the application
must disclose the claimed subject matter in compliance with 35 U.S.C. § 112, first
paragraph (emphasis added). In re Gosteli, 872 F.2d at 1010, 10 USPQ2d at 1616; In re
Scheiber, 587 F.2d 59, 61, 199 USPQ 782, 783-784 (CCPA 1978).
Compliance with the "written description" requirement of §112 is a question
of fact and each case must be decided on its own facts. Vas-Cath, 935 F.2d at 1563, 19
10
Page: Previous 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 Next
Last modified: November 3, 2007